Cimavax-EGF: Cuban lung cancer vaccine
Cuba does not leave the front pages of newspapers. The cause this time is Cimavax-EGF, the first therapeutic vaccine discovered helping to slow the progression and metastasis of lung cancer, fourth leading cause of death in the Caribbean island.
Precisely in the context of rapprochement between Cuba and the United States, it occurred yesterday the signing of an agreement between researchers from Roswell Park Cancer Institute and the Cuban Center of Molecular Immunology: first step in the conduct of clinical trials in the United States and approved by the FDA for marketing that would be an achievement of research in Cuba and a step for the treatment of a disease with a mortality rate of over 50% of cases a year of being detected.
Although the vaccine does not directly attack the affected cells, it generates antibodies in the patient's own body and slows cell growth and disease progression. It is expected that as a result of new phases of clinical trials can expand its application to other cancers.